Broadcom completes VMware acquisition, bolstering its AI and software capabilities. Read why potential investors should be cautious of AVGO stock.

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take a look at where Broadcom Inc. (NASDAQ:AVGO) stands against the other large cap dividend growth stocks.

Here are 5 things investors need to know today. 1. Stock Futures Move Higher to Start Shortened Trading Week. Stock futures moved higher ahead in premarket trading to start a shor

Jim Keller's career has been shaped by interactions with some of the most influential figures in the semiconductor industry. As Jim Keller entered his forties, he met a figure at Broadcom who left a profound impression on him—Henry Samueli.

Stanley Druckenmiller's Duquesne Family Office closed out holdings in Microsoft (NASDAQ:MSFT), Broadcom (AVGO), Mid-America (MAA), and Camden Property (CPT), according to its latest 13F filing. New positions include 1.

Broadcom and Taiwan Semiconductor Manufacturing Company (TSMC) are separately exploring deals to take over parts of Intel, according to a report in The

Broadcom's subscription model and streamlining boost margins but add risk. Click here to find out why AVGO stock is a Hold.

Artificial intelligence has been the driving force behind the stock market’s gains since late 2022. The debut of ChatGPT that November demonstrated the practical capabilities of generative AI, leading to heightened investor enthusiasm for AI-related companies.

Broadcom Inc. (AVGO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

At an event today in Manhattan and streamed worldwide, the IEEE announced Henry Samueli, one of the two founders of Broadcom, will be the recipient of the organization's top award, the Medal of Honor for 2025.

Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.